<DOC>
	<DOCNO>NCT03099109</DOCNO>
	<brief_summary>The purpose study evaluate safety study drug know LY3321367 , anti-T-cell immunoglobulin mucin-domain domain-containing molecule-3 ( TIM-3 ) antibody administer alone combination LY3300054 , anti-programmed death ligand 1 ( PD-L1 ) antibody , participant advance relapsed/refractory solid tumor .</brief_summary>
	<brief_title>A Study LY3321367 Alone With LY3300054 Participants With Advanced Relapsed/Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>For Ph1a monotherapy combination cohort , histologic cytologic confirmation advance solid tumor . For Phase 1a 1b , prior PD1 PDL1 therapy immunotherapy allow , follow criterion meet : Must experience toxicity lead permanent discontinuation prior immunotherapy . Must completely recover recovered baseline prior screen prior AEs occur receive prior immunotherapy . Must experience Grade â‰¥3 immunerelated AE immunerelated neurologic ocular AE , pneumonitis cardiomyopathy grade receive prior immunotherapy . Must require immunosuppressive agent , corticosteroid management adverse event currently requite maintenance dos &gt; 10 milligram ( mg ) prednisone ( equivalent ) per day . Must least 1 measurable lesion assessable use standard technique Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) . Must provide tumor tissue sample , follow : For participant enter Ph1a : submit , available , archival tumor tissue sample . For participant enter Ph1b : submit , sample newly obtain core excisional biopsy tumor lesion recent biopsy define 6 month study enrollment ( Ph1b ) . Must performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Must adequate organ function . Have estimate life expectancy 12 week , judgement investigator . Have symptomatic uncontrolled brain metastasis , spinal cord compression , leptomeningeal disease require concurrent treatment , include limited surgery , radiation , and/or corticosteroid ( participant receive anticonvulsant eligible ) . Have receive live vaccine within 30 day first dose study treatment . If female , pregnant , breastfeeding , plan become pregnant . Have history current evidence condition , therapy , laboratory abnormality might interfere participant 's participation . Have moderate severe cardiovascular disease . Have serious concomitant systemic disorder would compromise participant 's ability adhere protocol , include active chronic infection human immunodeficiency virus ( HIV ) , active hepatitis B virus ( HBV ) , active hepatitis C virus ( HCV ) , active autoimmune disorder , prior document severe autoimmune inflammatory disorder require immunosuppressive treatment . Use escalate chronic supraphysiologic dos corticosteroids immunosuppressive agent ( , cyclosporine ) . [ Use topical , ophthalmic , inhaled , intranasal corticosteroid permit ] . Bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection . Evidence interstitial lung disease noninfectious pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>TIM-3</keyword>
	<keyword>PD-L1</keyword>
</DOC>